Skip to main content
Fig. 3 | BMC Endocrine Disorders

Fig. 3

From: Dual A1 and A2A adenosine receptor antagonists, methoxy substituted 2-benzylidene-1-indanone, suppresses intestinal postprandial glucose and attenuates hyperglycaemia in fructose-streptozotocin diabetic rats

Fig. 3

(A) glucose-lowering effect of A1 and A2 AR antagonist on non-fasting plasma glucose measured before diabetes induction and throughout the weeks of intervention. (B) AUC data for 0–4th week blood glucose are shown. Baseline subtraction for normal control was used to calculate AUC values for all groups, to ensure full treatment benefits are recognised. Values represent mean ± SD for 6 rats. a−e Different alphabets near the lines for a given time (3 A) or bar (3B) for a given time or group respectively represent significance of difference (p < 0.05). * significance of difference P < 0.05 compared to Diabetic control group. NC, Normal Control; DBC, Diabetic Control; DBI, Diabetic + 2-BI; DCA, Diabetic + caffeine; DIS, Diabetic + istradefylline; DPX, Diabetic + DPXPC; DBM, Diabetic Metformin; DGT, Diabetic + pioglitazone

Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us